Reduced incidence and severity of acute radiation mucositis by WF10 (IMMUNOKINE) as adjunct to standard of cure in the management of head & neck cancer patients
- PMID: 17926989
Reduced incidence and severity of acute radiation mucositis by WF10 (IMMUNOKINE) as adjunct to standard of cure in the management of head & neck cancer patients
Abstract
Objective: To evaluate the role of WF10-immunotherapy in reducing oro-pharyngeal complications in head and neck cancer chemoradiotherapy.
Material and method: Thirteen patients were enrolled and assigned either to WF10- (n = 6) or control group (n = 7). After completion of their initial (neoadjuvant) chemotherapy, patients received WF10 intravenous infusions at 0.5 mL/kg body weight/day for five consecutive days and repeated every 3 weeks, concomitantly to standard radiotherapy (6,600-7,500 cGy, 200 cGy/day). Control patients received radiotherapy alone.
Results: Patients in the WF10-group had a lower incidence of oro-pharyngeal complications grade > 2, including oral mucositis (1 vs. 5), dysphagia (2 vs. 7), oral pain (3 vs. 5), taste alteration (4 vs. 6) and weight loss (2 vs. 4). The statistical significances were achieved for the parameters of oral mucositis (p = 0. 048) and dysphagia (p = 0.009).
Conclusion: WF10 appears to reduce severity of oro-pharyngeal complications associated with standard chemoradiotherapy for head and neck cancer.
Similar articles
-
Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial.Radiother Oncol. 2004 Nov;73(2):179-85. doi: 10.1016/j.radonc.2004.05.007. Radiother Oncol. 2004. PMID: 15542165 Clinical Trial.
-
Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.Australas Radiol. 2006 Oct;50(5):468-74. doi: 10.1111/j.1440-1673.2006.01628.x. Australas Radiol. 2006. PMID: 16981945 Clinical Trial.
-
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):643-50. doi: 10.1016/j.ijrobp.2006.09.043. Int J Radiat Oncol Biol Phys. 2007. PMID: 17293228 Clinical Trial.
-
Nasopharyngeal carcinoma: current management, future directions and dental implications.Oral Oncol. 2008 Jul;44(7):617-27. doi: 10.1016/j.oraloncology.2007.08.003. Epub 2007 Dec 3. Oral Oncol. 2008. PMID: 18061518 Review.
-
Radiation treatment breaks and ulcerative mucositis in head and neck cancer.Oncologist. 2008 Aug;13(8):886-98. doi: 10.1634/theoncologist.2008-0024. Epub 2008 Aug 13. Oncologist. 2008. PMID: 18701763 Review.
Cited by
-
Relation of mucous membrane alterations to oral intake during the first year after treatment for head and neck cancer.Head Neck. 2011 Jun;33(6):774-9. doi: 10.1002/hed.21542. Epub 2010 Aug 24. Head Neck. 2011. PMID: 20737496 Free PMC article.
-
WF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells.J Biomed Biotechnol. 2011;2011:436587. doi: 10.1155/2011/436587. Epub 2011 May 3. J Biomed Biotechnol. 2011. PMID: 21629753 Free PMC article.
-
Interventions for preventing oral mucositis for patients with cancer receiving treatment.Cochrane Database Syst Rev. 2011 Apr 13;2011(4):CD000978. doi: 10.1002/14651858.CD000978.pub5. Cochrane Database Syst Rev. 2011. PMID: 21491378 Free PMC article.
-
The pro-oxidative drug WF-10 inhibits serial killing by primary human cytotoxic T-cells.Cell Death Discov. 2016 Jul 25;2:16057. doi: 10.1038/cddiscovery.2016.57. eCollection 2016. Cell Death Discov. 2016. PMID: 27551545 Free PMC article.